Øystein Soug
Chief Executive Officer bij Arxx Therapeutics AS
Profiel
Øystein Soug is currently the Chief Executive Officer at Arxx Therapeutics AS and a Director at Pharmasum Therapeutics AS.
He previously worked as a Director at Bionor Pharma ASA in 2013, Chief Financial Officer-Russian Division at Orkla ASA, CFO, Head-Finance, Administration & IR at Algeta ASA from 2012 to 2013, and Chief Financial Officer at Circio Holding ASA from 2015 to 2022.
He graduated from the University of St. Gallen in 1997.
Actieve functies van Øystein Soug
| Bedrijven | Functie | Begin |
|---|---|---|
Pharmasum Therapeutics AS
 Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Director/Board Member | - |
Arxx Therapeutics AS
 Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Chief Executive Officer | 01-01-2022 |
Eerdere bekende functies van Øystein Soug
| Bedrijven | Functie | Einde |
|---|---|---|
| CIRCIO HOLDING ASA | Chief Executive Officer | 20-10-2021 |
| ORKLA ASA | Director of Finance/CFO | - |
Bionor Pharma ASA
 Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Director/Board Member | - |
| ALGETA ASA | Director of Finance/CFO | - |
Opleiding van Øystein Soug
| University of St. Gallen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ORKLA ASA | Consumer Non-Durables |
| CIRCIO HOLDING ASA | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Bionor Pharma ASA
Bionor Pharma ASA Pharmaceuticals: OtherHealth Technology Bionor Pharma ASA engages in research and development, patenting, and commercialization of products in the pharmaceuticals and biotech industry. The company focuses on the research and development of peptide-based vaccines against viral diseases, primarily HIV. The company was founded on January 2, 1993 and is headquartered in Oslo, Norway. | Health Technology |
Pharmasum Therapeutics AS
Pharmasum Therapeutics AS BiotechnologyHealth Technology Pharmasum Therapeutics AS operates as a pharmaceutical company. The firm focuses on the discovery and development of novel human medicines for the treatment of brain diseases, especially neurological diseases. The company was founded by Anders Fugelli and John Sigurd Svendsen is headquartered in Kvaloysletta, Norway. | Health Technology |
Arxx Therapeutics AS
Arxx Therapeutics AS BiotechnologyHealth Technology Arxx Therapeutics AS develops therapeutics for fibrotic diseases. The company is based in Oslo, Norway. The Norwegian company was founded in 2015 by Jonas Hallén, Jörg Klingelhöfer. Øystein Soug has been the CEO of the company since 2022. | Health Technology |
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
